Gemcitabine  Chemical Structure

Gemcitabine Chemical Structure
Molecular Weight: 263.2

Validation & Quality Control

Customer Product Validation(3)

Quality Control & MSDS

Related Compound Libraries

Gemcitabine is available in the following compound libraries:

Product Information

  • Compare DNA/RNA Synthesis Inhibitors
    Compare DNA/RNA Synthesis Products
  • Research Area

Product Description

Biological Activity

Description Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]
In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Hertel LW, et al. Cancer Res, 1990, 50(14), 4417-4422.

[2] Bruns CJ, et al. Clin Cancer Res, 2000, 6(5), 1936-1948.

view more

Clinical Trial Information( data from, updated on 2015-08-29)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT02336087 Not yet recruiting Metastatic Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer City of Hope Medical Center|National Cancer Institute (NCI) January 2016 Phase 1
NCT01676259 Not yet recruiting Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer Silenseed Ltd December 2015 Phase 2
NCT02506959 Not yet recruiting Multiple Myeloma M.D. Anderson Cancer Center|Novartis Pharmaceuticals December 2015 Phase 2
NCT02024009 Not yet recruiting Pancreatic Neoplasms (Locally Advanced Non-metastatic) University of Oxford|Celgene Corporation|Cancer Research UK November 2015 Phase 1|Phase 2
NCT02383433 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Case Comprehensive Cancer Center|National Cancer Institut  ...more Case Comprehensive Cancer Center|National Cancer Institute (NCI) November 2015 Phase 2

view more

Chemical Information

Download Gemcitabine SDF
Molecular Weight (MW) 263.2


CAS No. 95058-81-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms LY-188011, NSC 613327
Solubility (25°C) * In vitro DMSO 15 mg/mL (56.99 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2'-​deoxy-​2',​2'-​difluoro-cytidine

Customer Product Validation (3)

Click to enlarge
Source Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck
Method Immunofluorescence
Cell Lines HeLa cells
Concentrations 100 nM
Incubation Time 72 h
Results To finally investigate whether incorporation of drugs into RNA could be a general mechanism inducing SG assembly, we tested other chemotherapeutics known to incorporate into RNA, such as 5-azacytidine and 6-thioguanine, or as control, chemotherapeutics known to incorporate mainly into DNA, such as trifluorothymidine (TFT) or gemcitabine. HeLa cells treated with 5-azacytidine and 6-thioguanine displayed TIAR-positive foci, whereas HeLa cells treated with TFT or gemcitabine did exhibit such foci even with higher concentrations applied.

Click to enlarge
Source Pancreas 2015 44(1), 144-151. Gemcitabine purchased from Selleck
Method Immunohistochemical staining
Cell Lines Male athymic nude mice
Concentrations 125 mg/kg
Incubation Time 41 days
Results It displays the effect of Lut, Gemcitabine, and Lut + Gem in pancreatic tumor tissue on the expression of K-ras, GSK-3 β , P (Tyr216)GSK-3 β (active form), and P(Ser311)NF- κ B p65 (active form). In A, single-agent Lut and Gemcitabine treatments resulted in nonsignificant effects in the expression of K-ras (upstream GSK-3 β effector) of 20% (P = 0.122) and 16% (P = 0.293), respectively, whereas Lut + Gemcitabine treatment resulted in a signifi cant reduction of 46% (P = 0.0006). In B, Lut and Gemcitabine treatments resulted in nonsignificant effects in the expression of GSK-3 β of 8% (P = 0.762) and 17% (P = 0.593), respectively, whereas Lut + Gemcitabine treatment resulted in a significant reduction of 34% (P = 0.0014). In C, Lut and Gem treatments resulted in nonsignificant effects in the expression of P(Tyr216) GSK-3 β of 10% (P = 0.261) and 8% (P = 0.174), respectively, whereas Lut + Gem treatment resulted in a significant reduction of 16% (P = 0.033). In D, Lut and Gem treatments resulted in nonsignificant decreases in the expression of P(Ser311)NF- κ B. p65 of 12% (P = 0.418) and 11% (P = 0.503), respectively, whereas Lut + Gem treatment resulted in a significant reduction of 27% (P = 0.036).

Click to enlarge
Source Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck
Method MTT assays
Cell Lines MCF7 cells, MCF10A cells
Concentrations 0.01-100 μM
Incubation Time 48 h
Results Gemcitabine potently inhibited the survival of MCF10A cells in a dose-dependent manner. The highest level of inhibition was observed with Gemcitabine HCl in concentration of 0.01 μM in MCF7 cells

Product Use Citation (13)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related DNA/RNA Synthesis Products

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • Blasticidin S HCl

    Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

  • Sofosbuvir (PSI-7977, GS-7977)

    Sofosbuvir (PSI-7977, GS-7977) is a HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Oxaliplatin

    Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

  • Carboplatin

    Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

    Features:A DNA synthesis inhibitor.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is an DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

  • Cytarabine

    Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

    Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Recently Viewed Items

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
Contact Us